Anturol FDA Approval History
FDA Approved: Yes (Discontinued) (First approved December 7, 2011)
Brand name: Anturol
Generic name: oxybutynin
Dosage form: Gel
Company: Antares Pharma, Inc.
Treatment for: Overactive Bladder
Marketing Status: Discontinued
Anturol (oxybutynin) is an anticholinergic transdermal gel formulation indicated for the management of overactive bladder.
Development timeline for Anturol
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.